manufacturing science and technology

Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat cancer and autoimmune diseases. Its platform is based on a naturally occurring subset of NK cells deficient in the FceR1g protein, derived from healthy donors. The company is based in Houston, TX, and Seattle, WA.

Read more

cell therapy developmentclinical developmentG-NK cell expansion process